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Purpose: Epidermal growth factor receptor (EGFR) gene copy
number obtained by fluorescence in situ hybridization (FISH) has
been recently found to predict treatment outcome in non-small cell
lung cancer (NSCLC) patients receiving EGFR tyrosine kinase
inhibitors. However, it is still unknown whether EGFR status differs
in metastases compared with primary NSCLC. In all studies FISH
have been performed on histologic material. The possibility to
perform FISH analysis on cytologic material obtained by fine-needle
aspiration from superficial and visceral metastases would allow us to
know the real EGFR status avoiding invasive diagnostic procedures.
Methods: EGFR gene copy number was analyzed by FISH on
fine-needle aspirates obtained from 31 patients with metastatic
NSCLC and the results were compared with those obtained on
corresponding paraffin histologic sections from the primary tumor.
Results: The feasibility of EGFR FISH on cytology was 90% (28 of
31 patients). EGFR FISH was positive in 61% (17 of 28 patients) of
the metastases and in 36% (10 of 28 patients) of the primary tumors.
Nine of the 28 cases (32%) were EGFR positive on both primary
tumor and metastatic site and 10 (36%) were negative on both
primary tumor and metastasis. Nine of the 28 cases (32%) showed
discordance of primary tumor versus metastasis (McNemar test; p
0.041).
Conclusions: EGFR FISH can be reliably assessed on fine-needle
aspirates obtained from NSCLC metastases. We found that EGFR
gene copy number is discordant between primary NSCLC and the
corresponding distant metastatic sites in a significant proportion of
cases. These findings should be considered in future studies de-
signed to elucidate the predictive role of EGFR FISH in NSCLC.
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Approximately one third of all cancer-related deaths inWestern countries are because of lung cancer. Non-small
cell lung cancer (NSCLC) represents 75 to 80% of lung
cancer cases and accounts for approximately 1.2 million new
cases worldwide each year.1 The current standard of care for
patients with advanced NSCLC is systemic chemotherapy.
However, this treatment does not result in cure and nearly all
patients succumb to their disease.2
During the last few years, significant advances in the
development of new molecularly targeted agents have been
made. One example of such targets is the epidermal growth
factor receptor (EGFR), a tyrosine kinase receptor overex-
pressed in many human epithelial malignancies, including
NSCLC. After stimulation by its natural ligands, this receptor
initiates signal transduction cascades that promote cell divi-
sion, migration, angiogenesis, and inhibit apoptosis.3
Gefitinib and erlotinib, small molecules that reversibly
target EGFR, represent a new reality in the treatment of
NSCLC, although only a limited percentage of patients seem
to benefit from such agents. Patients with higher probability
of response seem to be those of female sex, never smokers, of
Asian ethnicity, with histology of adenocarcinoma (ADK)
and, particularly, with ADK with bronchioloalveolar-like
growth pattern.4 The discovery that specific EGFR gene
mutations in the tyrosine kinase domain (in exons 18–21)
account for increased sensitivity to gefitinib or erlotinib has
opened a new avenue for NSCLC patient selection.5 Recent
studies have suggested that EGFR gene copy number as-
sessed by fluorescence in situ hybridization (FISH) or EGFR
immunohistochemistry (IHC) could be used to predict which
patients will respond to EGFR tyrosine kinase inhibitors
(TKIs).6
One potential limitation of these studies, however, was
their reliance on surgical specimens to obtain sufficient ma-
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terial for immunohistochemical, mutational, and FISH anal-
yses. Unfortunately, many NSCLC cases present at diagnosis
in advanced stage when operation is not recommended. In
these cases, the samples available for analysis are typically of
low volume such as fine-needle aspirate (FNA) cytologic
material, obtained as diagnostic procedure. Therefore, in the
clinical practice the diagnosis of most patients is made on
cytology. Therefore it seems extremely important to test the
feasibility and reliability of EGFR status on NSCLC cyto-
logic specimens. In a previous study, we demonstrated the
feasibility and reliability of HER-2/neu FISH characterization
in cytologic samples from breast distant metastases.7 Besides,
it is still unknown whether EGFR biology differs in metas-
tases compared with primary NSCLC.
The aim of the current study was to evaluate the
feasibility of EGFR assessment by FISH on cytologic sam-
ples from distant NSCLC metastases and to compare the
results with those obtained by FISH on histologic sections
from the primary tumor.
MATERIALS AND METHODS
The current series included cytologic specimens obtained
by FNA, for diagnostic purpose, from 31 patients with advanced
NSCLC who presented with metastatic lesions localized to liver
(n  2), pleura (n  2), abdomen (n  1), ribs (n  2), skin
(n  4), and superficial lymphnodes (n  20).
Cytologic smears from each metastatic site were partly
submitted to May-Gru¨nwald-Giemsa (MGG) staining for rou-
tine cytologic diagnosis and partly to FISH for EGFR eval-
uation. In addition, EGFR FISH was assessed on paraffin-
embedded histologic sections obtained from corresponding
primary NSCLCs. Histologic specimens of primary tumors of
these patients were obtained from transbronchial biopsy in 14
cases and from operation in 17 cases, respectively. This study
was approved by the institutional ethical review board and
written informed consent was obtained from each patient
before enrollment.
EGFR FISH on Cytologic Smears
Sample Collection
Cytologic smears from superficial palpable metastatic
lesions (lymphnodes, skin, and ribs) were obtained by fine-
needle aspiration biopsy (FNAB) using a 22-gauge needle
and a 20-ml syringe, whereas nonpalpable metastases (liver
and abdomen) were sampled by ultrasound-guided FNAB.
The aspirated material obtained by FNAB from superficial or
deep metastatic lesions was smeared on glass slides and air
dried. Cellular suspensions obtained from pleural fluids were
cyto-centrifuged and partly air dried. At least two slides were
stained with MGG for routine cytology. The remaining slides
were kept unstained at room temperature until the assay.
After cytologic diagnosis of malignancy, one representative
slide was submitted to EGFR FISH.
Pretreatment of Cytologic Slides
Unstained slides were fixed in absolute methanol, air
dried, incubated in wash buffer (0.3% NP-40, 2 saline-
sodium citrate buffer [pH 7.0–7.5]) at 37°C for 30 minutes,
dehydrated through gradients of 70, 85, and 100% ethanol, air
dried, and processed by FISH. Archival cytologic slides, stained
with MGG, were treated with xylene to remove the coverslip
and rinsed twice for 10 minutes each in clean xylene. After
washing three times for 10 minutes each in Carnoy solution,
the slides were dehydrated gradually in ethanol and processed
by FISH. An alternative pretreatment with proteinase K was
required for destained smears demonstrating considerable
thickness. In this case, destained slides were dehydrated
through an ethanol gradient and incubated for 5 minutes at
37°C in 20 g/ml proteinase K. After washing in water and
ethanol dehydration, the slides were air dried before being
evaluated by FISH.
Fluorescence in Situ Hybridization
After pretreatment, FISH assays were performed using
the LSI EGFR Spectrum Orange/CEP 7 Spectrum Green
probe (Vysis, Downers Grove, IL). Samples were denatured
at 67°C for 5 minutes and hybridized overnight at 37°C in a
HY-Brite denaturation/hybridization system for FISH (Vy-
sis). The following day, slides were incubated in wash buffer
at 72°C for 2 minutes, air dried in the dark, and counter-
stained with 4,6-diamidino-2-phenylindole (DAPI). A posi-
tive control slide was included in each run. Slides were
viewed at a magnification of 1250 on an Olympus CX40
fluorescence microscope (Olympus, Inc., Melville, NY) using
a triple excitation/emission filter for simultaneous detection
of Spectrum Orange, Spectrum Green, and DAPI. At least
100 assessable nuclei for each case were scored visually.
Samples were classified as FISH positive both when at least
four copies of EGFR gene were found in more than 40% of
cells and in the presence of gene amplification (defined by
presence of signal clusters and a ratio of gene/chromosome
per cell 2, or 15 copies of the genes per cell in 10% of
analyzed cells).8,9
EGFR FISH on Paraffin Sections
Formalin-fixed, paraffin-embedded tissue sections were
cut into 4-m-thick sections that were incubated overnight at
56°C. Deparaffinization, pretreatment, enzyme digestion, and
fixation of slides were performed using the Vysis paraffin
pretreatment kit (Vysis) according to the manufacturer’s
recommended protocol. Denaturation and hybridization were
performed in a HY-Brite denaturation/hybridization system
for FISH (Vysis). LSI EGFR Spectrum Orange/CEP 7 Spec-
trum Green probe (Vysis) was applied to tissue sections that
were denatured at 72°C for 2 minutes and hybridized over-
night at 37°C. The slides were then washed in wash buffer at
72°C for 2 minutes and counterstained with DAPI. Control
slides (Vysis) were included in each assay run. For each
specimen, at least 100 cells were scored for both EGFR and
chromosome 7 signals by image analysis. FISH images were
processed at a magnification of 1250 utilizing an Olympus
MX60 fluorescence microscope with a 100 W mercury lamp.
Separate narrow band pass filters were used for the detection
of Spectrum Orange, Spectrum Green, and DAPI. Samples
were defined as EGFR positive or negative according to the
same criteria applied on cytologic samples.8,9
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Statistical Analysis
McNemar test was used to compare the EGFR FISH
status between primary tumors and related metastatic sites.
Differences were considered statistically significant when the
p value was 0.05 or less. All statistical tests were two-sided.
RESULTS
The characteristics of the 31 NSCLC patients are de-
scribed in Table 1. The median age of the patients at diag-
nosis was 65 years old (with a range of 44–80 years). There
were 19 men and 12 women. Five patients (16%) had squa-
mous cell carcinoma, 14 patients (45%) had ADK, and 12
(39%) had NSCLC not otherwise specified.
The thirty-one analyzed metastases (see above) were
synchronous in 17 cases (55%) and metachronous in 14 cases
(45%). In the metachronous metastases, the median interval
between resection of the primary tumor and FNAB from the
metastatic site was 19.5 months. None of the patients re-
ceived prior EGFR targeted therapy; all patients were sub-
mitted to first-line chemotherapy treatment (after FNA in
metastatic site).
EGFR FISH was assessable on 28 of the 31 archival
histologic sections from primary NSCLC and on 28 of the 31
cytologic samples from the corresponding metastatic sites (10
cytologic smears were originally unstained, whereas 21 were
destained from previous MGG staining). The feasibility of
EGFR FISH on both cytology and histology was 90% (28 of
31 patients): three samples were not assessable both on
cytology and histology because of lack of hybridization.
EGFR results obtained by FISH in the 28 assessable
primary NSCLC and the corresponding distant metastatic
lesions are shown in Table 2. EGFR FISH was positive in
36% (10 of 28 patients) of the primary tumors and in 61% (17
of 28 patients) of the metastatic sites. Among 10 cases of
EGFR FISH positive in the primary tumor, only two were
amplified.
Nine of the 28 cases (32%) were EGFR FISH posi-
tive on both primary tumor and metastatic site and 10
(36%) were negative on both primary tumor and metastasis
(Table 3). The two cases with EGFR gene amplification on
primary tumor showed only polisomy on the correspond-
ing metastatic site.
Nine of the 28 cases (32%) showed primary tumor
versus metastasis discordance (McNemar test; p  0.041): in
eight cases EGFR FISH was positive in the metastatic site but
not in the primary tumor, whereas one sample was EGFR
positive in the primary tumor but not in the metastasis.
EGFR FISH status in primary tumor and in the corre-
sponding synchronous or metachronous metastases is shown
TABLE 1. Patient Characteristics
No. of Patients
(n  31) Percent
Gender
Males 19 61
Females 12 39
Age (yr)
Median (range) 65 (44–80)
Histology
Squamous cell carcinoma 5 16
Adenocarcinoma 14 45
NSCLC, NOS 12 39
Stage at diagnosisa
I 5 16
II 7 23
III 8 26
IV 11 35
Metastatic sites analyzed
Liver 2 6
Pleura 2 6
Abdomen 1 3
Ribs 2 6
Skin 4 13
Lymphnodes 20 66
a Stage at the time of primary tissue sampling.
NSCLC, non-small cell lung cancer; NOS, not otherwise specified.
TABLE 2. EGFR Gene Assessed by FISH on Histologic
Samples from Primary NSCLC and on Cytologic Specimens
from Metastatic Sites
Case
Primary
Tumor
Metastatic
Site
EGFR
Primary
Tumor
EGFR
Metastatic
Site
1 NSCLC Left laterocervical ln Negative Negative
2 NSCLC Skin Negative Negative
3 ADK Left supraclavicular ln Negative Positive
4 NSCLC Pleural fluid Negative Negative
5 NSCLC Left rib Negative Negative
6 ADK Skin Negative Positive
7 SCC Liver Negative Negative
8 SCC Left supraclavicular ln Negative Negative
9 NSCLC Right supraclavicular ln Negative Positive
10 SCC Liver Negative Positive
11 SCC Skin Negative Positive
12 ADK Left supraclavicular ln Negative Negative
13 ADK Abdominal ln Negative Positive
14 ADK Right supraclavicular ln Negative Positive
15 NSCLC Right supraclavicular ln Negative Negative
16 ADK Right supraclavicular ln Positive Positive
17 ADK Left supraclavicular ln Positive Positive
18 NSCLC Right supraclavicular ln Positive Positive
19 ADK Right supraclavicular ln Positive Negative
20 NSCLC Right supraclavicular ln Positive Positive
21 NSCLC Left supraclavicular ln Positive Positive
22 NSCLC Pleural fluid Positive Positive
23 NSCLC Left rib Amplified Positive
24 ADK Left supraclavicular ln Amplified Positive
25 ADK Right supraclavicular ln Positive Positive
26 NSCLC Left supraclavicular ln Negative Positive
27 ADK Skin Negative Negative
28 ADK Right axillary ln Negative Negative
NSCLC, non-small cell lung cancer; ADK, adenocarcinoma; SCC, squamous cell
carcinoma; ln, lymphnode.
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in Table 4. No significant correlation was found, probably
because of the small simple size.
Five patients, after chemotherapy, received EGFR TKI
therapy (three gefitinib and two erlotinib, respectively). Two
patients demonstrated partial response and one stable disease
during gefitinib treatment, whereas two evidenced progres-
sive disease to erlotinib. About EGFR FISH in primary tumor
versus metastasis, four of these five cases were concordant
(two partial response and two progressive disease) and one,
the patient with stable disease, discordant (EGFR positive in
the primary tumor and negative in the metastasis; case num-
ber 19 of Table 2).
DISCUSSION
EGFR gene copy number is usually assessed by FISH
technique and it is generally performed only on primary
tumors, because recurrences are rarely neither removed nor
undergone biopsy. Consequently, data referring to EGFR
status in distant metastases are very limited.
The issue of EGFR expression consistency along the
metastatic process in NSCLC is still not solved. We could
assume that EGFR positivity of primary tumors incompletely
predicts the response to EGFR TKIs, because of a change of
EGFR status during metastatic progression. To select patients
who will achieve the maximum benefit from EGFR inhibi-
tors, it would be worth to ascertain the EGFR status in
metastatic lesions in comparison with the corresponding pri-
mary tumors, considering that in advanced NSCLC the main
targets of any therapy are the metastases.
Our data suggest that EGFR status does not remain
stable during the metastatic progression. In fact, the correla-
tion between EGFR FISH status in primary NSCLC cancer
and in the corresponding metastatic sites is relatively poor.
Nine of the 28 cases (32%) showed discordance of primary
tumor versus metastasis; in particular, the majority of cases
(eight of nine) were EGFR FISH positive in the metastasis
but not in the primary tumor.
Up to now, only one other report has compared EGFR
status in primary NSCLC with paired distant metastases,
showing that EGFR expression is not stable during metastatic
progression in a significant proportion of NSCLC.10 In this
study carried on 30 patients, EGFR status has been analyzed
by IHC and FISH either on tumor samples of primary
NSCLC or on biopsy samples obtained from one distant
metastatic site at least. Thirty-three percentage of the cases
showed primary tumor versus metastasis discordance by IHC
analysis and 27% by FISH.
This discordance also has been observed by Petersen et
al. who identified chromosomal imbalances of the 7p11
region, where the EGFR gene is mapped, by comparative
genomic hybridization in a series of paired primary tumor and
metastases of NSCLC.11 Moreover, recently Park et al. found
6 of 11 advanced NSCLC patients (54.5%) showing discor-
dance of EGFR mutation in the primary tumor versus metas-
tasis site.12 The lack of correlation of EGFR status between
primary and metastatic sites, determined by IHC, was also
demonstrated in colorectal cancer.13
Our finding that EGFR status may be discrepant be-
tween primary NSCLC and the corresponding distant meta-
static sites is novel and contributes to the debate about the
best method for predicting response of NSCLC tumors to
EGFR-targeted therapies. A switch from EGFR-negative sta-
tus in the primary tumor to positive in the metastatic site was
observed either in synchronous and in metachronous metas-
tases; however, the number of cases was too small to draw
any conclusion.
Moreover, it is necessary to consider chemotherapy
treatment that occur before the EGFR TKI therapy and that
could influence the EGFR status of metastatic disease. A
switch from EGFR IHC-negative status to positive in four of
six NSCLC patients undergone to preoperative chemotherapy
was reported.14 Based on EGFR mRNA expression, further
investigations suggest that some NSCLC (25%) EGFR-pos-
itive circulating tumor cells might convert to a negative status
on chemotherapy.15
In light of this observation, assuming that EGFR status
plays a role in prediction of TKI response, future trials should
consider, whenever feasible, a rebiopsy immediately before
starting gefitinib or erlotinib therapy. In our opinion, testing
EGFR status exclusively on primary NSCLC specimens may
be inadequate for planning an EGFR inhibitor therapy in
metastatic disease. Based on our data by FNAB, performed
on a NSCLC metastatic lesion, might represent an excellent
provider of fresh cytologic material for an updated charac-
terization of relevant predictive factors and a real-time EGFR
assessment for EGFR inhibitor-based therapy.
To our knowledge, none of the studies that evaluated
EGFR gene copy number by FISH on metastases from
NSCLC patients has been performed on cytologic material. In
TABLE 3. Correlation Between EGFR FISH Status in Primary
NSCLC and Corresponding Metastatic Site (Concordance 19
of 28 Patients, 68%)
EGFR FISH in Primary Tumor
FISH FISH Total
EGFR FISH in metastatic site
FISH 10 1 11
FISH  8 9 17
Total 18 10 28
TABLE 4. Correlation Between EGFR FISH Status in Primary
NSCLC and Corresponding Synchronous and Metachronous
Metastases
EGFR FISH in
Synchronous mts
EGFR FISH in
Metachronous mts
TotalFISH FISH FISH FISH
EGFR FISH in
primary tumor
FISH 5 3 5 5 18
FISH 1 6 0 3 10
Total 6 9 5 8 28
mts, metastases.
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our experience, FNAB guided by simple palpation for super-
ficial lesions and by ultrasound for visceral metastasis is a
relatively easy and safe method to obtain cellular material for
FISH analysis.7 This procedure has been proved to circum-
vent many methodologic limitations or interferences encoun-
tered on histologic material from primary NSCLC either by
IHC or FISH, particularly when applied on archival samples.
Previous studies have indicated that, in terms of feasibility
and accuracy, FISH provides a tempting alternative to immu-
nocytochemistry, whose specificity and sensitivity problems
have been described.16,17 Conversely, in archival histologic
specimens, later assessed by FISH, hybridization may be
eventually compromised by Bouin fixation.
In conclusion, since the advent of EGFR inhibitors, the
characterization of the molecular profile in metastatic disease
has become increasingly important for targeted therapy se-
lection. The results of the current study indicate the feasibil-
ity, the reliability, and the advantages of two relatively rapid
and informative techniques, such as FNA and FISH, per-
formed for ascertaining the malignant nature of a suspicious
lesion and determining predictive markers for response to
EGFR TKI therapy.
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